paliperidone both increase QTc interval. Modify Therapy/Monitor Closely.paliperidone and trazodone both increase sedation. Use Caution/Monitor.pancuroniumpancuronium and trazodone both decrease cholinergic effects/transmission. Use Caution/Monitor.papaveretumpapaveretum and trazodone both increase sedation. Use Caution/Monitor.papaverinetrazodone and papaverine both increase sedation. Use Caution/Monitor.parecoxibtrazodone, parecoxib. Either increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of upper GI bleeding. SSRIs inhib. serotonin uptake by platelets.paromomycintrazodone will decrease the level or effect of paromomycin by P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor.paroxetinetrazodone and paroxetine both increase QTc interval. Modify Therapy/Monitor Closely.pazopanibtrazodone and pazopanib both increase QTc interval. Use Caution/Monitor.peginterferon alfa 2bpeginterferon alfa 2b, trazodone. Other (see comment). Use Caution/Monitor. Comment: When patients are administered peginterferon alpha-2b with CYP2D6 substrates, the therapeutic effect of these drugs may be altered. Peginterferon alpha-2b may increase or decrease levels of CYP2D6 substrate.pentazocinepentazocine and trazodone both increase sedation. Use Caution/Monitor.trazodone and pentazocine both increase serotonin levels. Modify Therapy/Monitor Closely.pentobarbitalpentobarbital will decrease the level or effect of trazodone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.pentobarbital and trazodone both increase sedation. Use Caution/Monitor.perphenazineperphenazine and trazodone both increase sedation. Use Caution/Monitor.phendimetrazinetrazodone increases and phendimetrazine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.phenobarbitalphenobarbital will decrease the level or effect of trazodone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.phenobarbital and trazodone both increase sedation. Use Caution/Monitor.phenterminetrazodone increases and phentermine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.phenylephrinetrazodone increases and phenylephrine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.phenylephrine ophthalmictrazodone, phenylephrine ophthalmic. Other (see comment). Use Caution/Monitor. Comment: Tricyclic antidepressants increase or decrease effects of sympathomimetics, by blocking reuptake of NE, or blocking uptake of indirect sympathomimetics into the adrenergic neuron.phenylephrine POtrazodone increases and phenylephrine PO decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor. .pholcodinetrazodone and pholcodine both increase sedation. Use Caution/Monitor.pimozidepimozide and trazodone both increase sedation. Use Caution/Monitor.pirbuteroltrazodone increases and pirbuterol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.piroxicamtrazodone, piroxicam. Either increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of upper GI bleeding. SSRIs inhib. serotonin uptake by platelets.posaconazoletrazodone will decrease the level or effect of posaconazole by P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor.trazodone and posaconazole both increase QTc interval. Modify Therapy/Monitor Closely.pralidoximepralidoxime and trazodone both decrease cholinergic effects/transmission. Use Caution/Monitor.prednisolonetrazodone will decrease the level or effect of prednisolone by P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor.prednisoneprednisone will decrease the level or effect of trazodone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.trazodone will decrease the level or effect of prednisone by P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor.pregabalinpregabalin, trazodone. Either increases effects of the other by pharmacodynamic synergism. Modify Therapy/Monitor Closely. Coadministration of CNS depressants can result in serious, life-threatening, and fatal respiratory depression. Use lowest dose possible and monitor for respiratory depression and sedation.primidoneprimidone will decrease the level or effect of trazodone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.primidone and trazodone both increase sedation. Use Caution/Monitor.prochlorperazineprochlorperazine and trazodone both increase QTc interval. Use Caution/Monitor.prochlorperazine and trazodone both increase sedation. Use Caution/Monitor.promethazinepromethazine and trazodone both increase QTc interval. Use Caution/Monitor.promethazine and trazodone both increase sedation. Use Caution/Monitor.propanthelinepropantheline and trazodone both decrease cholinergic effects/transmission. Use Caution/Monitor.propofolpropofol and trazodone both increase sedation. Use Caution/Monitor.propylhexedrinetrazodone increases and propylhexedrine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.protriptylineprotriptyline and trazodone both decrease cholinergic effects/transmission. Use Caution/Monitor.protriptyline and trazodone both increase sedation. Use Caution/Monitor.quazepamquazepam and trazodone both increase sedation. Use Caution/Monitor.quetiapinequetiapine and trazodone both increase sedation. Use Caution/Monitor.quinupristin/dalfopristinquinupristin/dalfopristin will increase the level or effect of trazodone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.ramelteontrazodone and ramelteon both increase sedation. Use Caution/Monitor.ranolazinetrazodone and ranolazine both increase QTc interval. Modify Therapy/Monitor Closely.rapacuroniumrapacuronium and trazodone both decrease cholinergic effects/transmission. Use Caution/Monitor.remimazolamremimazolam, trazodone. Either increases toxicity of the other by sedation. Modify Therapy/Monitor Closely. Coadministration may result in profound sedation, respiratory depression, coma, and/or death. Continuously monitor vital signs during sedation and recovery period if coadministered. Carefully titrate remimazolam dose if administered with opioid analgesics and/or sedative/hypnotics.rifabutinrifabutin decreases levels of trazodone by increasing metabolism. Use Caution/Monitor.risperidonetrazodone will decrease the level or effect of risperidone by P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor.trazodone and risperidone both increase QTc interval. Modify Therapy/Monitor Closely.risperidone and trazodone both increase sedation. Use Caution/Monitor.ritonavirritonavir will increase the level or effect of trazodone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely.trazodone will decrease the level or effect of ritonavir by P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor.rizatriptanrizatriptan and trazodone both increase serotonin levels. Modify Therapy/Monitor Closely.rocuroniumrocuronium and trazodone both decrease cholinergic effects/transmission. Use Caution/Monitor.romidepsintrazodone will decrease the level or effect of romidepsin by P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor.rucaparibrucaparib will increase the level or effect of trazodone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Adjust dosage of CYP3A4 substrates, if clinically indicated.rufinamiderufinamide will decrease the level or effect of trazodone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.salicylates (non-asa)trazodone, salicylates (non-asa). Either increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of upper GI bleeding. SSRIs inhib. serotonin uptake by platelets.salmeteroltrazodone increases and salmeterol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.salsalatetrazodone, salsalate. Either increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of upper GI bleeding. SSRIs inhib. serotonin uptake by platelets.SAMetrazodone and SAMe both increase serotonin levels. Modify Therapy/Monitor Closely.scopolaminescopolamine and trazodone both decrease cholinergic effects/transmission. Use Caution/Monitor.scullcaptrazodone and scullcap both increase sedation. Use Caution/Monitor.secobarbitalsecobarbital will decrease the level or effect of trazodone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.secobarbital and trazodone both increase sedation. Use Caution/Monitor.sevofluranesevoflurane and trazodone both increase sedation. Use Caution/Monitor.shepherd's pursetrazodone and shepherd's purse both increase sedation. Use Caution/Monitor.silodosintrazodone will decrease the level or effect of silodosin by P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor.sirolimustrazodone will decrease the level or effect of sirolimus by P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor.solifenacinsolifenacin and trazodone both decrease cholinergic effects/transmission. Use Caution/Monitor.stiripentolstiripentol, trazodone. affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Stiripentol is a CYP3A4 inhibitor and inducer. Monitor CYP3A4 substrates coadministered with stiripentol for increased or decreased effects. CYP3A4 substrates may require dosage adjustment.streptomycintrazodone will decrease the level or effect of streptomycin by P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor.sufentanilsufentanil and trazodone both increase sedation. Use Caution/Monitor.sufentanil SLsufentanil SL, trazodone. Either increases effects of the other by serotonin levels. Use Caution/Monitor. Coadministration of drugs that affect the serotonergic neurotransmitter system may result in serotonin syndrome. If concomitant use is warranted, carefully observe the patient, particularly during treatment initiation and dose adjustment.sulfamethoxazoletrazodone and sulfamethoxazole both increase QTc interval. Modify Therapy/Monitor Closely.sulfasalazinetrazodone, sulfasalazine. Either increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of upper GI bleeding. SSRIs inhib. serotonin uptake by platelets.sulindactrazodone, sulindac. Either increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of upper GI bleeding. SSRIs inhib. serotonin uptake by platelets.sumatriptansumatriptan and trazodone both increase serotonin levels. Modify Therapy/Monitor Closely.sumatriptan intranasalsumatriptan intranasal and trazodone both increase serotonin levels. Modify Therapy/Monitor Closely.tacrolimustrazodone will decrease the level or effect of tacrolimus by P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor.tamsulosintrazodone increases levels of tamsulosin by affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor.tapentadoltapentadol and trazodone both increase sedation. Use Caution/Monitor.trazodone and tapentadol both increase serotonin levels. Modify Therapy/Monitor Closely.tazemetostattazemetostat will decrease the level or effect of trazodone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.trazodone will increase the level or effect of tazemetostat by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.tecovirimattecovirimat will decrease the level or effect of trazodone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Tecovirimat is a weak CYP3A4 inducer. Monitor sensitive CYP3A4 substrates for effectiveness if coadministered.telavancintrazodone and telavancin both increase QTc interval. Modify Therapy/Monitor Closely.temazepamtemazepam and trazodone both increase sedation. Use Caution/Monitor.terbutalinetrazodone increases and terbutaline decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.thioridazinethioridazine and trazodone both increase sedation. Use Caution/Monitor.thiothixenethiothixene and trazodone both increase sedation. Use Caution/Monitor.tinidazoletrazodone will increase the level or effect of tinidazole by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.tiotropiumtiotropium and trazodone both decrease cholinergic effects/transmission. Use Caution/Monitor.tobramycintrazodone will decrease the level or effect of tobramycin by P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor.tolfenamic acidtrazodone, tolfenamic acid. Either increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of upper GI bleeding. SSRIs inhib. serotonin uptake by platelets.tolmetintrazodone, tolmetin. Either increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of upper GI bleeding. SSRIs inhib. serotonin uptake by platelets.tolterodinetolterodine and trazodone both decrease cholinergic effects/transmission. Use Caution/Monitor.tolvaptantrazodone will decrease the level or effect of tolvaptan by P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor.topiramatetopiramate will decrease the level or effect of trazodone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.trazodone and topiramate both increase sedation. Modify Therapy/Monitor Closely.tramadoltramadol and trazodone both increase sedation. Use Caution/Monitor.trazodone and tramadol both increase serotonin levels. Modify Therapy/Monitor Closely.triazolamtriazolam and trazodone both increase sedation. Use Caution/Monitor.triclabendazoletriclabendazole and trazodone both increase QTc interval. Use Caution/Monitor.triclofostriclofos and trazodone both increase sedation. Use Caution/Monitor.trifluoperazinetrifluoperazine and trazodone both increase sedation. Use Caution/Monitor.trimethoprimtrazodone and trimethoprim both increase QTc interval. Modify Therapy/Monitor Closely.trimipraminetrazodone and trimipramine both decrease cholinergic effects/transmission. Use Caution/Monitor.trazodone and trimipramine both increase sedation. Use Caution/Monitor.triprolidinetriprolidine and trazodone both increase sedation. Use Caution/Monitor.triptorelintriptorelin increases toxicity of trazodone by QTc interval. Use Caution/Monitor. Increases risk of torsades de pointes.tropisetrontrazodone and tropisetron both increase QTc interval. Modify Therapy/Monitor Closely.trospium chloridetrospium chloride and trazodone both decrease cholinergic effects/transmission. Use Caution/Monitor.valbenazinevalbenazine and trazodone both increase QTc interval. Use Caution/Monitor.vecuroniumvecuronium and trazodone both decrease cholinergic effects/transmission. Use Caution/Monitor.venlafaxinetrazodone and venlafaxine both increase QTc interval. Modify Therapy/Monitor Closely.verapamilverapamil will increase the level or effect of trazodone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.vinblastinetrazodone will decrease the level or effect of vinblastine by P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor.vincristinetrazodone will decrease the level or effect of vincristine by P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor.vincristine liposomaltrazodone will decrease the level or effect of vincristine liposomal by P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor.voriconazoletrazodone and voriconazole both increase QTc interval. Modify Therapy/Monitor Closely.xylometazolinetrazodone increases and xylometazoline decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.yohimbinetrazodone increases and yohimbine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.ziconotidetrazodone and ziconotide both increase sedation. Use Caution/Monitor.ziprasidoneziprasidone and trazodone both increase sedation. Use Caution/Monitor.zolmitriptanzolmitriptan and trazodone both increase serotonin levels. Modify Therapy/Monitor Closely.Minor (131)acarbosetrazodone increases effects of acarbose by pharmacodynamic synergism. Minor/Significance Unknown.acetazolamideacetazolamide will increase the level or effect of trazodone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.almotriptantrazodone, almotriptan. Mechanism: unknown. Minor/Significance Unknown. Risk of weakness, dyspnea, chest pain.alvimopantrazodone will decrease the level or effect of alvimopan by P-glycoprotein (MDR1) efflux transporter. Minor/Significance Unknown.amobarbitalamobarbital, trazodone. Other (see comment). Minor/Significance Unknown. Comment: Barbiturates may increase adverse effects, including respiratory depression, produced by toxic doses of TCAs. With therapeutic doses of TCAs, barbiturates increase metabolism and decrease blood concentrations of TCAs.anastrozoleanastrozole will increase the level or effect of trazodone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.anticholinergic/sedative combosanticholinergic/sedative combos and trazodone both decrease cholinergic effects/transmission. Minor/Significance Unknown.armodafiniltrazodone will decrease the level or effect of armodafinil by P-glycoprotein (MDR1) efflux transporter. Minor/Significance Unknown.atorvastatintrazodone increases levels of atorvastatin by unspecified interaction mechanism. Minor/Significance Unknown.atropineatropine and trazodone both decrease cholinergic effects/transmission. Minor/Significance Unknown.trazodone increases levels of atropine by unknown mechanism. Minor/Significance Unknown.atropine IV/IMtrazodone increases levels of atropine IV/IM by unknown mechanism. Minor/Significance Unknown.bazedoxifene/conjugated estrogensbazedoxifene/conjugated estrogens, trazodone. Mechanism: unspecified interaction mechanism. Minor/Significance Unknown. Estrogens and progestins may decr tricyclic antidepressant effects, while increasing TCA plasma concentration and adverse effects.belladonna alkaloidsbelladonna alkaloids and trazodone both decrease cholinergic effects/transmission. Minor/Significance Unknown.benztropinebenztropine and trazodone both decrease cholinergic effects/transmission. Minor/Significance Unknown.bethanecholbethanechol increases and trazodone decreases cholinergic effects/transmission. Effect of interaction is not clear, use caution. Minor/Significance Unknown.brimonidinetrazodone decreases effects of brimonidine by pharmacodynamic antagonism. Minor/Significance Unknown.bumetanidebumetanide, trazodone. Mechanism: pharmacodynamic synergism. Minor/Significance Unknown. Possible additive hyponatremia.butabarbitalbutabarbital, trazodone. Other (see comment). Minor/Significance Unknown. Comment: Barbiturates may increase adverse effects, including respiratory depression, produced by toxic doses of TCAs. With therapeutic doses of TCAs, barbiturates increase metabolism and decrease blood concentrations of TCAs.butalbitalbutalbital, trazodone. Other (see comment). Minor/Significance Unknown. Comment: Barbiturates may increase adverse effects, including respiratory depression, produced by toxic doses of TCAs. With therapeutic doses of TCAs, barbiturates increase metabolism and decrease blood concentrations of TCAs.carbacholcarbachol increases and trazodone decreases cholinergic effects/transmission. Effect of interaction is not clear, use caution. Minor/Significance Unknown.carbamazepinecarbamazepine decreases levels of trazodone by increasing metabolism. Minor/Significance Unknown.celandinecelandine decreases effects of trazodone by pharmacodynamic antagonism. Minor/Significance Unknown. Based on animal studies.cevimelinecevimeline increases and trazodone